Drug Type AAV based gene therapy |
Synonyms A002(MeiraGTx Holdings Plc), Adenovirus Associated Viral Vector Serotype 8 Containing The Human Cngb3 Gene, Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene - MeiraGTx + [5] |
Target |
Mechanism CNGB3 gene stimulants(Cyclic nucleotide-gated cation channel beta-3 gene stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Color Vision Defects | Phase 2 | US | 03 Jan 2023 | |
Achromatopsia 1 | Phase 2 | US | 29 Jun 2017 | |
Achromatopsia 1 | Phase 2 | GB | 29 Jun 2017 |
Phase 1/2 | 23 | (Low Dose AAV - CNGB3) | hlmbivpyot(rzmaajsert) = tadavibrqs imgsyavacg (bzdhhxtoid, elhadxsqpn - orrdurpodk) View more | - | 08 Mar 2023 | ||
(Intermediate Dose AAV-CNGB3) | hlmbivpyot(rzmaajsert) = hnqmayvrhq imgsyavacg (bzdhhxtoid, wpjvywgayt - bfdwdfmbrr) View more |